Oric Pharmaceuticals (NASDAQ:ORIC) Stock: Insider Dominic Piscitelli Sells 14,000 Shares

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 14,000 shares of Oric Pharmaceuticals stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total transaction of $189,420.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares in the company, valued at $944,772.84. This trade represents a 16.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dominic Piscitelli also recently made the following trade(s):

• On Monday, September 28th, Dominic Piscitelli sold 13,400 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.53, for a total value of $181,302.00.
• On Thursday, September 24th, Dominic Piscitelli sold 600 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.50, for a total value of $8,100.00.
• On Wednesday, August 26th, Dominic Piscitelli sold 77,000 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.69, for a total value of $1,054,130.00.

Oric Pharmaceuticals Price Performance

NASDAQ:ORIC opened at $13.63 on Friday. The business has a fifty day simple moving average of $12.94 and a two-hundred day simple moving average of $11.01. Oric Pharmaceuticals, Inc. has a 1 year low of $7.23 and a 1 year high of $14.68.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.02). On average, equities analysts predict that Oric Pharmaceuticals, Inc. will post -1.53 EPS for the current year.

Hedge Funds Weigh In On Oric Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Quantinno Capital Management LP grew its position in shares of Oric Pharmaceuticals by 9.3% in the first quarter. Quantinno Capital Management LP now owns 25,526 shares of the company’s stock valued at $323,000 after purchasing an additional 2,170 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Oric Pharmaceuticals by 1.4% during the 1st quarter. Bank of New York Mellon Corp now owns 190,470 shares of the company’s stock valued at $2,413,000 after purchasing an additional 2,549 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Oric Pharmaceuticals during the 2nd quarter worth about $38,000. Quantbot Technologies LP purchased a new stake in Oric Pharmaceuticals during the 2nd quarter worth about $46,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Oric Pharmaceuticals by 17.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,470 shares of the company’s stock worth $687,000 after purchasing an additional 9,231 shares in the last quarter. 95.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ORIC shares. Leerink Partners started coverage on Oric Pharmaceuticals in a research note on Monday, October 5th. They issued an “outperform” rating and a $26.00 price objective on the stock. Wall Street Zen raised shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. JPMorgan Chase & Co. increased their target price on shares of Oric Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. HC Wainwright lifted their target price on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Finally, BTIG Research started coverage on shares of Oric Pharmaceuticals in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $26.00 price target on the stock. Fourteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $21.17.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing medicines that overcome mechanisms of treatment resistance in cancer. The company uses its discovery platform to identify therapies intended to improve or restore the effectiveness of existing cancer treatments.

Oric’s pipeline has included ORIC-533, an oral small-molecule inhibitor of CD73 designed to block adenosine-mediated immunosuppression in the tumor microenvironment. The company has evaluated the program in hematologic malignancies, including multiple myeloma.